What we do Abbott India Ltd operates as a leading multinational pharmaceutical company in India, manufacturing and marketing healthcare products across various therapeutic areas including Gastroenterology, Women's Health, Metabolics, CNS, Vaccines, and Multi-Specialty. |
Founded in 1,944 |
Market share Abbott India holds strong leadership in GI, Metabolics, CNS, and Women's Health sectors with continuous above-market growth and top brand positions like Thyronorm and Digene. |
Problem solved Abbott India addresses critical health challenges by providing innovative pharmaceuticals and vaccines targeting chronic and acute diseases to improve patient outcomes. |
Top clients or who we serve The company serves healthcare professionals, hospitals, and patients across India, operating primarily in B2B and B2C healthcare markets. |
Key management Mr. Kartik Rajendran, Managing Director since June 2025, leads with rich pharmaceutical industry experience driving growth and innovation. |
Our journey and innovations Since 1944, evolving through multiple name changes, Abbott India has expanded capacity, launched over 70 new products recently, and pioneered therapies in GI and Women's Health. |
Where we operate Primarily India with limited export revenues; over 98% revenue from Indian market. |
Top products or what we offer Key offerings include Brufen, Thyronorm, Digene, Duphalac, Duphaston, Pneumoshield vaccine, and other specialty care products. |
Top brands Thyronorm (#1 thyroid treatment), Digene (top antacid), Duphaston (#1 Women’s Health), Brufen (pain relief), Pneumoshield vaccine (pediatric immunization). |
Raw materials needed Active pharmaceutical ingredients and excipients sourced globally and domestically. |
Raw materials supplier Suppliers include various pharmaceutical ingredient manufacturers in India and abroad. |
Recurring vs cyclical contribution Majority of revenues are recurring from pharmaceutical sales; some cyclicality in vaccine volumes and new product launches. |
Our industry position Among top multinational pharma in India with continuous above-market growth, strong portfolio in niche specialty segments. |
Financial highlights FY2024-25 revenues Rs 6409 Cr (9.6% growth), Profit After Tax Rs 1414 Cr (17.7% growth). Strong margin and cash generation. |
Geographical revenue split 99% India, 1% Outside India. |
Order book - |
Whats driving growth New product launches, therapy shaping, multi-channel physician engagement, expanding Women's Health and GI portfolios. |
Our future plans Expand innovative product pipeline, strengthen hybrid promotional models, enhance patient support programs, and deepen specialty segment presence. |
Our green promise Strong environmental management including zero waste to landfill certification, water stewardship, and plastic waste management compliance. |
Our people and values 3,659 employees with focus on diversity, equity, inclusion, and leadership development programs. |
Key challenges ahead Regulatory pressures, generic competition, API supply challenges, and need for continual innovation. |
Interesting facts Awarded Most Innovative MNC of the Year 2019; pioneering use of digital and patient-centric healthcare initiatives. |
Risks and strategy Mitigates regulatory and supply risks via compliance frameworks; strategy emphasizes portfolio diversification and digital engagement. |
